TITLE:
Treatment for Symptomatic Peripheral Neuropathy in Patients With Diabetes

CONDITION:
Diabetic Neuropathies

INTERVENTION:
Ruboxistaurin mesylate

SUMMARY:

      The purpose of this protocol is to determine if an investigational drug known as LY333531 is
      effective in treating nerve malfunction in diabetes.
    

DETAILED DESCRIPTION:
NONE

ELIGIBILITY:
Gender: All
Age: 18 Years to N/A
Criteria:

        Inclusion Criteria:

          -  Patients must have type I or type II Diabetes Mellitus.

          -  Have clinically diagnosed positive sensory symptoms such as numbness, lancinating
             pain, burning pain, aching pain, allodynia and prickling sensation that have been
             present not greater than 5 years but stable for 6 months.

          -  Has a HbA1C less than or equal to 12%. Patients with HbA1C greater than 9% must be
             insulin therapy.

          -  Must be 18 years or older.

          -  Be able to visit the doctor's office approximately 3 times over a maximum of a 6-week
             period to determine if you can continue in the study.

        Exclusion Criteria:

          -  History of significant liver problems.

          -  Have poor kidney function.

          -  Drink an excess of alcohol or abuse drugs.

          -  Have recently participated or currently participating in a Medical study in which you
             receive an experimental drug.

          -  Are a woman and are pregnant or breastfeeding, intend to become pregnant within the
             next 2 years or a woman not using effective birth control.
      
